Revised U.S.-Korea FTA Grants Three-year Grace Period To Korean Generic Drug Makers
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Despite discontent among opposition parties in South Korea with the recently revised Free Trade Agreement with the U.S., Korea's generic drug makers are welcoming new supplementary agreements, which they say would give them a three-year grace period during which they could launch generic versions of patented products
You may also be interested in...
Efforts To Adopt Path-Breaking Pharmaceutical Global Trade Rules In TPP Remains Work-In-Progress
Efforts to get a major new trade bloc to adopt stronger pharmaceutical intellectual property rules, including a potential path breaking agreement on biologics data exclusivity remains a work-in-progress, trade negotiators said at the end of the 18th round of the Trans-Pacific Partnership talks. But hope still floats the diverse group of 12 countries might find compromise language.
Korea FDA Moves To Elevate Patent-Approval Team To A Division
As it implements provisions in the U.S.-South Korea FTA, KFDA is creating a division to oversee patent-approval issues, upgrading the status and manpower of a temporary task force team.
Korea-U.S. FTA Takes Effect March 15; Pharma Companies Assess Changing Landscape
Nearly six years after negotiations started, the bilateral FTA between South Korea and the U.S. finally takes effect in March amid worries in Korea that it could ultimately harm generic-dependent local pharma companies.